<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066703</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 25-02 / BIG 3-02</org_study_id>
    <secondary_id>IBCSG 25-02</secondary_id>
    <secondary_id>BIG 3-02</secondary_id>
    <secondary_id>NABCI IBCSG 25-02</secondary_id>
    <secondary_id>EU-20347</secondary_id>
    <secondary_id>2004-000168-28</secondary_id>
    <secondary_id>CDR0000316458</secondary_id>
    <nct_id>NCT00066703</nct_id>
  </id_info>
  <brief_title>Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer</brief_title>
  <acronym>TEXT</acronym>
  <official_title>A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
      triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of
      estrogen. It is not yet known whether giving triptorelin together with exemestane is more
      effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer.

      PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how
      well they work compared to triptorelin and tamoxifen in treating premenopausal women with
      hormone-responsive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the disease-free survival, breast cancer-free interval, distant recurrence-free
           interval and overall survival of premenopausal women with endocrine-responsive breast
           cancer when treated with triptorelin and exemestane vs triptorelin and tamoxifen.

        -  Compare the quality of life, including late side effects of early menopause, of patients
           treated with these regimens.

      OUTLINE: This is a randomized, international, multicenter study. Patients are stratified
      according to planned use of concurrent adjuvant chemotherapy (yes vs no), and number of
      positive lymph nodes (0 vs 1 or more). Treatment duration is 5 years. Patients are followed
      every 3 months for 1 year, every 6 months for 5 years, and then annually thereafter. Quality
      of life is assessed at baseline, every 6 months for 2 years, and annually for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>5-year estimate reported at a median follow-up of 72 months</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer-free Interval</measure>
    <time_frame>5-year estimate reported at a median follow-up of 72 months</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to the invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Recurrence-free Interval</measure>
    <time_frame>5-year estimates reported at a median follow-up of 72 months</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free interval is defined as the time from randomization to breast cancer recurrence at a distant site; or censored at date of last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5-year estimates</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2672</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>T+OFS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E+OFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <arm_group_label>E+OFS</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <arm_group_label>T+OFS</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <arm_group_label>T+OFS</arm_group_label>
    <arm_group_label>E+OFS</arm_group_label>
    <other_name>GnRH analogue</other_name>
    <other_name>Trelstar Depot</other_name>
    <other_name>Decapeptyl Depot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast cancer

          -  Completely resected disease

               -  No clinically detectable residual loco-regional axillary disease

               -  Prior surgery for primary breast cancer of 1 of the following types:

                    -  Total mastectomy with or without adjuvant radiotherapy

                    -  Breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial
                       mastectomy with margins negative* for invasive disease and ductal carcinoma
                       in situ) with planned radiotherapy NOTE: *If all other margins are clear a
                       positive posterior (deep) margin is permitted, provided the excision was
                       performed down to the pectoral fascia and all tumor has been removed OR a
                       positive anterior (superficial; abutting skin) margin is allowed provided
                       all tumor was removed

          -  Tumor confined to the breast and axillary nodes

               -  Tumor detected in internal mammary chain nodes by sentinel node procedure and is
                  not enlarged is allowed

          -  Axillary lymph node dissection or a negative axillary sentinel node biopsy required

               -  Patients with negative or microscopically positive axillary sentinel nodes are
                  eligible

               -  Positive sentinel nodes must have either axillary dissection or radiation of
                  axillary nodes

          -  No distant metastases

          -  No locally advanced inoperable breast cancer, including any of the following:

               -  Inflammatory breast cancer

               -  Supraclavicular node involvement

               -  Enlarged internal mammary nodes (unless pathologically negative)

          -  Bilateral synchronous invasive breast cancer allowed if disease meets all other
             eligibility criteria

          -  No prior ipsilateral or contralateral invasive breast cancer

          -  Hormone receptor status:

               -  Estrogen and/or progesterone receptor positive

                    -  At least 10% of the tumor cells positive by immunohistochemistry

                    -  If &gt; 1 breast tumor, each tumor must be hormone receptor positive

        PATIENT CHARACTERISTICS:

        Age

          -  Premenopausal

        Sex

          -  Female

        Menopausal status

          -  Premenopausal

               -  Estradiol in the premenopausal range after prior surgery OR meets the following
                  criteria:

                    -  Menstruating regularly for the past 6 months

                    -  Has not used any form of hormonal treatment (including hormonal
                       contraception) within the past 6 months

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  No systemic hepatic disease that would preclude prolonged follow-up

        Renal

          -  No systemic renal disease that would preclude prolonged follow-up

        Cardiovascular

          -  No systemic cardiovascular disease that would preclude prolonged follow-up

          -  No prior thrombosis (e.g., deep vein thrombosis) and/or embolism unless patient is
             medically suitable

        Pulmonary

          -  No systemic pulmonary disease that would preclude prolonged follow-up

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective nonhormonal contraception

          -  No history of noncompliance to medical regimens

          -  No other nonmalignant systemic disease that would preclude prolonged follow-up

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, nonbreast carcinoma in situ, contralateral or ipsilateral
             carcinoma in situ of the breast, or other nonrecurrent invasive nonbreast malignancy,
             including any of the following:

               -  Stage I papillary thyroid cancer

               -  Stage IA carcinoma of the cervix

               -  Stage IA or B endometrioid endometrial cancer

               -  Borderline or stage I ovarian cancer

          -  No psychiatric, addictive, or other disorder that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior or concurrent neoadjuvant or adjuvant trastuzumab allowed

        Chemotherapy

          -  No prior neoadjuvant or adjuvant chemotherapy

        Endocrine therapy

          -  No prior tamoxifen, other selective estrogen-receptor modulators (SERMs) (e.g.,
             raloxifene), or hormone replacement therapy for more than 1 year before breast cancer
             diagnosis

          -  No prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer

          -  No concurrent oral or transdermal hormonal therapy

          -  No other concurrent estrogen, progesterone, or androgens

          -  No other concurrent aromatase inhibitors

          -  No concurrent oral or other hormonal contraceptives (i.e., implants or depot
             injections)

        Radiotherapy

          -  See Disease Characteristics

          -  No prior ovarian radiotherapy

        Surgery

          -  See Disease Characteristics

          -  No prior bilateral oophorectomy

        Other

          -  No concurrent bisphosphonates, except in the following cases:

               -  Bone density is at least 1.5 standard deviations below the young adult normal
                  mean

               -  Participation in a randomized clinical study testing bisphosphonates in the
                  adjuvant breast cancer setting

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivia Pagani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Walley, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Holy Cross Cancer Center</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91346-9600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Regional Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center at Roseville Medical Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby L. Golleher Cancer Program at Presbyterian Intercommunity Hospital</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaw Regional Cancer Center</name>
      <address>
        <city>Edwards</city>
        <state>Colorado</state>
        <zip>81632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Front Range Cancer Specialists</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06360-2875</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center - Coeur d'Alene</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resurrection Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Institute</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic, LLC</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514-2098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart General Hospital</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Community Hospital</name>
      <address>
        <city>Kokomo</city>
        <state>Indiana</state>
        <zip>46904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Therapy at LaPorte Hospital and Health Services</name>
      <address>
        <city>La Porte</city>
        <state>Indiana</state>
        <zip>46350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Regional Medical Center</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology-Oncology, PC - South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology Associates, LLP</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Chanute</name>
      <address>
        <city>Chanute</city>
        <state>Kansas</state>
        <zip>66720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Dodge City</name>
      <address>
        <city>Dodge City</city>
        <state>Kansas</state>
        <zip>67801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - El Dorado</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Independence</name>
      <address>
        <city>Independence</city>
        <state>Kansas</state>
        <zip>67301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence Memorial Hospital</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <zip>66044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Parsons</name>
      <address>
        <city>Parsons</city>
        <state>Kansas</state>
        <zip>67357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Pratt</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Salina</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shawnee Mission Medical Center</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Cancer Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wellington</name>
      <address>
        <city>Wellington</city>
        <state>Kansas</state>
        <zip>67152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Womens Health, PA - North Review</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Cancer Center at Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Kansas</state>
        <zip>67156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital Regional Cancer Therapy Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethke Cancer Center at Emerson Hospital</name>
      <address>
        <city>Concord</city>
        <state>Massachusetts</state>
        <zip>01742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addison Gilbert Hospital</name>
      <address>
        <city>Gloucester</city>
        <state>Massachusetts</state>
        <zip>01930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSMC Cancer Center - Peabody</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidMichigan Medical Center - Midland</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Care Center - St. Joseph</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeside Cancer Specialists, PLLC</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Cancer Care at St. John's Hospital</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422-2900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center - Hospital Hill</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute at Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin &amp; Edith Scarpa Regional Cancer Center at South Jersey Healthcare</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Virtua Health Cancer Program at Virtua West Jersey</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Mercy Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randolph Hospital</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203-5400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals - Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope A Women's Cancer Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone Regional Cancer Center at Wesley Long Community Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403-1198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pardee Memorial Hospital</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annie Penn Cancer Center</name>
      <address>
        <city>Reidsville</city>
        <state>North Carolina</state>
        <zip>27320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Cancer Care Center at MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Hazleton Cancer Center</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Group - Scenery Park</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical X-Ray Center, PC</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center at Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Cancer Center at Erlanger Hospital - Baroness</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Cancer Center at Jackson-Madison County General Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Hospital of Laredo</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountainview Medical</name>
      <address>
        <city>Berlin</city>
        <state>Vermont</state>
        <zip>05602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center at West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Langlade Memorial Hospital</name>
      <address>
        <city>Antigo</city>
        <state>Wisconsin</state>
        <zip>54409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Memorial Hospital of Burlington</name>
      <address>
        <city>Burlington</city>
        <state>Wisconsin</state>
        <zip>53105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Alliance - Franklin</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Alliance, SC - Milwaukee - East</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53212-1038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Alliance - Kenosha South</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Advanced Healthcare East Mequon Clinic</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia-Saint Mary's Hospital-Ozaukee</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53097</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Saint Mary's Water Tower Medical Commons Milwaukee</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Alliance, SC - Milwaukee - South</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Center - Racine</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53406-5661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Center - Waukesha</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconcin Cancer Center at Aspirus Wausau Hospital</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Alliance, SC - Milwaukee - West</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy Centre at Campbelltown Hospital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lismore Base Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy Centre at Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tamworth Base Hospital</name>
      <address>
        <city>Tamworth</city>
        <state>New South Wales</state>
        <zip>2340</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manning Base Hospital</name>
      <address>
        <city>Taree</city>
        <state>New South Wales</state>
        <zip>2430</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tweed Heads Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Unit Mercy Private</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital - Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maroondah Hospital</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Hutois</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute at University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor Leon Richard Oncology Centre</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre - Mississauga Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre at Windsor Regional Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo Oncology Center</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Klinikum Mittelbaden</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76532</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Deggendorf</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik des Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsfrauenklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Frauenklinik Goettingen</name>
      <address>
        <city>Gttingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius - Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein - Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsfrauenklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwaebisch Gmuend Stauferklinik</name>
      <address>
        <city>Mutlangen</city>
        <zip>D-73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg - Klinikum Nord</name>
      <address>
        <city>Nuremberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas - Krankenhaus Saint Josef</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Obergoeltzsch Rodewisch</name>
      <address>
        <city>Rodewisch</city>
        <zip>08228</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landkreis Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Ramazzini</name>
      <address>
        <city>Carpi</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>I-27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Misericordia e Dolce Hospital</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>2020</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology - Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2121</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Linkoping</name>
      <address>
        <city>Linkoping</city>
        <zip>S-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Hospital</name>
      <address>
        <city>Skovde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncocare Sonnenhof-Klinik Engeriedspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie-Praxis ZeTup Chur</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;la Carita&quot;, Locarno</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civico</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough Hospitals Trust</name>
      <address>
        <city>Peterborough</city>
        <state>England</state>
        <zip>PE3 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <state>England</state>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Francis P, Fleming G, Nasi ML, et al.: Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: the SOFT, TEXT, and PERCHE trials. [Abstract] The Breast 12 (Suppl 1): A-P104, S44, 2003.</citation>
  </reference>
  <reference>
    <citation>Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thrlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD; SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul;19(7):1231-41. doi: 10.1093/annonc/mdn037. Epub 2008 Mar 5.</citation>
    <PMID>18325918</PMID>
  </reference>
  <reference>
    <citation>Rabaglio M, Ruepp B; Soft/Text/Perche Steering Committee. Death due to liver failure during endocrine therapy for premenopausal breast cancer. Acta Oncol. 2010 Aug;49(6):874-6. doi: 10.3109/0284186X.2010.484813.</citation>
    <PMID>20482225</PMID>
  </reference>
  <reference>
    <citation>Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA; International Breast Cancer Study; GroupSOFT and TEXT Investigators. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec;22(6):1094-100. doi: 10.1016/j.breast.2013.08.009. Epub 2013 Oct 2.</citation>
    <PMID>24095609</PMID>
  </reference>
  <results_reference>
    <citation>Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.</citation>
    <PMID>24881463</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <results_first_submitted>July 14, 2015</results_first_submitted>
  <results_first_submitted_qc>March 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2016</results_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2672 patients were randomized between 7Nov03 and 7Apr11 at 182 centers in 15 countries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>T+OFS</title>
          <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
        </group>
        <group group_id="P2">
          <title>E+OFS</title>
          <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1334"/>
                <participants group_id="P2" count="1338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="722"/>
                <participants group_id="P2" count="756"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
                <participants group_id="P2" count="582"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment ongoing</title>
              <participants_list>
                <participants group_id="P1" count="346"/>
                <participants group_id="P2" count="311"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat population excludes 12 patients who immediately withdrew consent, were at a non-adherent center, or had inadequate documentation of informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>T+OFS</title>
          <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
        </group>
        <group group_id="B2">
          <title>E+OFS</title>
          <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1328"/>
            <count group_id="B2" value="1332"/>
            <count group_id="B3" value="2660"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="40" upper_limit="46"/>
                    <measurement group_id="B2" value="43" lower_limit="39" upper_limit="46"/>
                    <measurement group_id="B3" value="43" lower_limit="40" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1328"/>
                    <measurement group_id="B2" value="1332"/>
                    <measurement group_id="B3" value="2660"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymph-node status</title>
          <description>Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor size</title>
          <description>Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=2 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=2 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor grade</title>
          <description>Tumor grade is the histologic grade according to the BRE method. The method involves assessment of tumor morphology, including tubule formation, nuclear pleomorphism and frequency of mitoses. Grades are recorded according to criteria as 1,2 or 3. Grade 3 is associated with poor prognosis. Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HER2 status</title>
          <description>Units in this baseline measure reflect the percentage of total participants, rather than number of participants. The total provided does not equal the total number of participants and should not be interpreted as an accurate total of participants.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow up.</description>
        <time_frame>5-year estimate reported at a median follow-up of 72 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>T+OFS</title>
            <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
          </group>
          <group group_id="O2">
            <title>E+OFS</title>
            <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow up.</description>
          <population>Intention-to-treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1328"/>
                <count group_id="O2" value="1332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="85.7" upper_limit="88.7"/>
                    <measurement group_id="O2" value="91.1" lower_limit="89.7" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.717</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.602</ci_lower_limit>
            <ci_upper_limit>0.855</ci_upper_limit>
            <estimate_desc>T+OFS is the reference group in the estimation of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Cancer-free Interval</title>
        <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to the invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.</description>
        <time_frame>5-year estimate reported at a median follow-up of 72 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>T+OFS</title>
            <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
          </group>
          <group group_id="O2">
            <title>E+OFS</title>
            <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cancer-free Interval</title>
          <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to the invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.</description>
          <population>Intention-to-treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1328"/>
                <count group_id="O2" value="1332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" lower_limit="87.3" upper_limit="90.1"/>
                    <measurement group_id="O2" value="92.8" lower_limit="91.6" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.664</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.548</ci_lower_limit>
            <ci_upper_limit>.804</ci_upper_limit>
            <estimate_desc>T+OFS is the reference group for the estimation of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Recurrence-free Interval</title>
        <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free interval is defined as the time from randomization to breast cancer recurrence at a distant site; or censored at date of last follow-up</description>
        <time_frame>5-year estimates reported at a median follow-up of 72 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>T+OFS</title>
            <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
          </group>
          <group group_id="O2">
            <title>E+OFS</title>
            <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Recurrence-free Interval</title>
          <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free interval is defined as the time from randomization to breast cancer recurrence at a distant site; or censored at date of last follow-up</description>
          <population>Intention-to-treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1328"/>
                <count group_id="O2" value="1332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="90.7" upper_limit="93.1"/>
                    <measurement group_id="O2" value="93.8" lower_limit="92.7" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.777</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.624</ci_lower_limit>
            <ci_upper_limit>0.967</ci_upper_limit>
            <estimate_desc>T+OFS was the reference group in the estimation of the hazard ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.</description>
        <time_frame>5-year estimates</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every 3 months for the first year, then every 6 months until year 6. Reported at a median follow-up of 72 months.</time_frame>
      <desc>Targeted adverse events and other grade 3 or higher adverse events were collected on CRFs, regardless of attribution. The safety population EXCLUDES patients who never started protocol-assigned therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>T+OFS</title>
          <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
        </group>
        <group group_id="E2">
          <title>E+OFS</title>
          <description>Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="484" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="496" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis (e.g., immune hemolytic anemia, drug related hemolysis, other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura or hemolytic uremic syndrome)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Cardiac/heart</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Supraventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, high (hyperthyroidism, thyrotoxicosis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Endocrine-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GI - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Varices (rectal)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Perforation, GI - Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Stricture/stenosis (including anastomotic), GI - Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Ulcer, GI - Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, GI - Gallbladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/Pancreas-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Gallbladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Allergy/Immunology-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Foreign body (e.g., graft, implant)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Foreign body (e.g., graft, implant, prosthesis, stent)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) w/Grade 3 or 4 neutrophils -Catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Middle ear (otitis media)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Nerve-peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Pelvis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Salivary gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Soft tissue NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Infection-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Intra-operative injury - Ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Intra-operative injury - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Vessel injury-vein - Extremity-upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesterolemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusion capacity (DL(co))</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>GGT (gamma-glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pancreatic endocrine: glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity-upper (function)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Lymphedema-related fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy-possibly related to cancer treatment (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Neurology-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial - CN V Motor-jaw muscles; Sensory-facial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Obstruction, GU - Ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU - Uterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Breast nipple/areolar deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Irregular menses (change from baseline)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Sexual/Reproductive Function-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Obstruction/stenosis of airway - Larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Vascular-Other (Specify)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1293" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1298" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="446" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="478" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="807" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="760" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pancreatic endocrine: glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="388" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="588" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="953" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1030" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="738" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="714" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="555" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="592" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="610" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="336" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="374" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="611" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="683" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="752" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="705" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="1081" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="1076" subjects_at_risk="1317"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="1321"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="1317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rudolf Maibach, Executive Officer for International Trial Activities</name_or_title>
      <organization>IBCSG</organization>
      <phone>+41 31 389 91 96</phone>
      <email>rudolf.maibach@ibcsg.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

